nodes	percent_of_prediction	percent_of_DWPC	metapath
MACITENTAN—ALB—Acitretin—psoriasis	0.182	0.212	CbGbCtD
MACITENTAN—ALB—Mycophenolate mofetil—psoriasis	0.0853	0.0992	CbGbCtD
MACITENTAN—ALB—Prednisone—psoriasis	0.0682	0.0793	CbGbCtD
MACITENTAN—CYP2C19—Cholecalciferol—psoriasis	0.0638	0.0742	CbGbCtD
MACITENTAN—CYP3A4—Calcitriol—psoriasis	0.0599	0.0696	CbGbCtD
MACITENTAN—CYP3A4—Methoxsalen—psoriasis	0.0466	0.0541	CbGbCtD
MACITENTAN—CYP2C19—Prednisone—psoriasis	0.0442	0.0514	CbGbCtD
MACITENTAN—CYP2C19—Cyclosporine—psoriasis	0.0419	0.0487	CbGbCtD
MACITENTAN—ALB—Methotrexate—psoriasis	0.0342	0.0398	CbGbCtD
MACITENTAN—CYP3A4—Cholecalciferol—psoriasis	0.0308	0.0358	CbGbCtD
MACITENTAN—CYP2C19—Dexamethasone—psoriasis	0.0276	0.0321	CbGbCtD
MACITENTAN—CYP3A4—Mycophenolate mofetil—psoriasis	0.0267	0.0311	CbGbCtD
MACITENTAN—CYP3A4—Triamcinolone—psoriasis	0.0267	0.0311	CbGbCtD
MACITENTAN—CYP3A4—Betamethasone—psoriasis	0.0229	0.0267	CbGbCtD
MACITENTAN—CYP3A4—Prednisolone—psoriasis	0.0226	0.0263	CbGbCtD
MACITENTAN—CYP3A4—Hydrocortisone—psoriasis	0.0215	0.0249	CbGbCtD
MACITENTAN—CYP3A4—Prednisone—psoriasis	0.0214	0.0248	CbGbCtD
MACITENTAN—CYP3A4—Cyclosporine—psoriasis	0.0203	0.0236	CbGbCtD
MACITENTAN—CYP3A4—Dexamethasone—psoriasis	0.0133	0.0155	CbGbCtD
MACITENTAN—Nasopharyngitis—Beclomethasone—psoriasis	0.00344	0.0253	CcSEcCtD
MACITENTAN—Nasopharyngitis—Fluocinonide—psoriasis	0.00341	0.0251	CcSEcCtD
MACITENTAN—Hepatotoxicity—Hydroxyurea—psoriasis	0.00334	0.0246	CcSEcCtD
MACITENTAN—Pharyngitis—Beclomethasone—psoriasis	0.00264	0.0195	CcSEcCtD
MACITENTAN—Oedema—Tazarotene—psoriasis	0.00245	0.0181	CcSEcCtD
MACITENTAN—Nasopharyngitis—Calcitriol—psoriasis	0.0024	0.0177	CcSEcCtD
MACITENTAN—Hepatotoxicity—Cyclosporine—psoriasis	0.00226	0.0167	CcSEcCtD
MACITENTAN—Nasopharyngitis—Fluocinolone Acetonide—psoriasis	0.00213	0.0157	CcSEcCtD
MACITENTAN—Infection—Clobetasol propionate—psoriasis	0.00206	0.0152	CcSEcCtD
MACITENTAN—Influenza—Fluocinolone Acetonide—psoriasis	0.00206	0.0151	CcSEcCtD
MACITENTAN—Fluid retention—Mycophenolic acid—psoriasis	0.00205	0.0151	CcSEcCtD
MACITENTAN—Urinary tract infection—Calcitriol—psoriasis	0.00201	0.0148	CcSEcCtD
MACITENTAN—Infection—Beclomethasone—psoriasis	0.00188	0.0138	CcSEcCtD
MACITENTAN—Infection—Fluocinonide—psoriasis	0.00186	0.0137	CcSEcCtD
MACITENTAN—Nervous system disorder—Fluocinonide—psoriasis	0.00184	0.0135	CcSEcCtD
MACITENTAN—Infestation NOS—Fluocinolone Acetonide—psoriasis	0.00183	0.0135	CcSEcCtD
MACITENTAN—Infestation—Fluocinolone Acetonide—psoriasis	0.00183	0.0135	CcSEcCtD
MACITENTAN—Urinary tract infection—Acitretin—psoriasis	0.00179	0.0132	CcSEcCtD
MACITENTAN—Fluid retention—Cyclosporine—psoriasis	0.00166	0.0122	CcSEcCtD
MACITENTAN—Pharyngitis—Acitretin—psoriasis	0.00164	0.0121	CcSEcCtD
MACITENTAN—Fluid retention—Mycophenolate mofetil—psoriasis	0.00162	0.0119	CcSEcCtD
MACITENTAN—Fluid retention—Prednisolone—psoriasis	0.00151	0.0111	CcSEcCtD
MACITENTAN—Angiopathy—Acitretin—psoriasis	0.0015	0.011	CcSEcCtD
MACITENTAN—Oedema—Methoxsalen—psoriasis	0.00148	0.0109	CcSEcCtD
MACITENTAN—Fluid retention—Hydrocortisone—psoriasis	0.00148	0.0109	CcSEcCtD
MACITENTAN—Infection—Methoxsalen—psoriasis	0.00147	0.0108	CcSEcCtD
MACITENTAN—Infestation NOS—Hydroxyurea—psoriasis	0.00144	0.0106	CcSEcCtD
MACITENTAN—Infestation—Hydroxyurea—psoriasis	0.00144	0.0106	CcSEcCtD
MACITENTAN—Nasopharyngitis—Mycophenolic acid—psoriasis	0.0014	0.0103	CcSEcCtD
MACITENTAN—Fluid retention—Triamcinolone—psoriasis	0.00139	0.0102	CcSEcCtD
MACITENTAN—Hypotension—Methoxsalen—psoriasis	0.00138	0.0102	CcSEcCtD
MACITENTAN—Influenza—Mycophenolic acid—psoriasis	0.00136	0.00999	CcSEcCtD
MACITENTAN—Bronchitis—Mycophenolic acid—psoriasis	0.0013	0.00961	CcSEcCtD
MACITENTAN—Headache—Clobetasol propionate—psoriasis	0.0013	0.00959	CcSEcCtD
MACITENTAN—Fluid retention—Betamethasone—psoriasis	0.00126	0.00929	CcSEcCtD
MACITENTAN—Fluid retention—Dexamethasone—psoriasis	0.00126	0.00929	CcSEcCtD
MACITENTAN—Hepatotoxicity—Methotrexate—psoriasis	0.00125	0.00922	CcSEcCtD
MACITENTAN—Infestation NOS—Mycophenolic acid—psoriasis	0.00121	0.00891	CcSEcCtD
MACITENTAN—Infestation—Mycophenolic acid—psoriasis	0.00121	0.00891	CcSEcCtD
MACITENTAN—Headache—Beclomethasone—psoriasis	0.00118	0.00873	CcSEcCtD
MACITENTAN—Angiopathy—Hydroxyurea—psoriasis	0.00118	0.00866	CcSEcCtD
MACITENTAN—Urinary tract infection—Mycophenolic acid—psoriasis	0.00118	0.00866	CcSEcCtD
MACITENTAN—Headache—Fluocinonide—psoriasis	0.00117	0.00865	CcSEcCtD
MACITENTAN—Oedema—Acitretin—psoriasis	0.00117	0.00864	CcSEcCtD
MACITENTAN—Oedema—Fluocinolone Acetonide—psoriasis	0.00117	0.00861	CcSEcCtD
MACITENTAN—Infection—Acitretin—psoriasis	0.00117	0.00858	CcSEcCtD
MACITENTAN—Infection—Fluocinolone Acetonide—psoriasis	0.00116	0.00856	CcSEcCtD
MACITENTAN—Nervous system disorder—Fluocinolone Acetonide—psoriasis	0.00115	0.00845	CcSEcCtD
MACITENTAN—Fluid retention—Prednisone—psoriasis	0.0011	0.00809	CcSEcCtD
MACITENTAN—Pharyngitis—Mycophenolic acid—psoriasis	0.00108	0.00794	CcSEcCtD
MACITENTAN—Influenza—Mycophenolate mofetil—psoriasis	0.00107	0.00788	CcSEcCtD
MACITENTAN—Bronchitis—Cyclosporine—psoriasis	0.00106	0.00777	CcSEcCtD
MACITENTAN—Anaemia—Hydroxyurea—psoriasis	0.00104	0.00768	CcSEcCtD
MACITENTAN—Bronchitis—Mycophenolate mofetil—psoriasis	0.00103	0.00758	CcSEcCtD
MACITENTAN—Angiopathy—Mycophenolic acid—psoriasis	0.000985	0.00725	CcSEcCtD
MACITENTAN—Infestation—Cyclosporine—psoriasis	0.000978	0.00721	CcSEcCtD
MACITENTAN—Infestation NOS—Cyclosporine—psoriasis	0.000978	0.00721	CcSEcCtD
MACITENTAN—Infestation NOS—Mycophenolate mofetil—psoriasis	0.000954	0.00703	CcSEcCtD
MACITENTAN—Infestation—Mycophenolate mofetil—psoriasis	0.000954	0.00703	CcSEcCtD
MACITENTAN—Urinary tract infection—Cyclosporine—psoriasis	0.000951	0.007	CcSEcCtD
MACITENTAN—Urinary tract infection—Mycophenolate mofetil—psoriasis	0.000928	0.00683	CcSEcCtD
MACITENTAN—Headache—Methoxsalen—psoriasis	0.000927	0.00683	CcSEcCtD
MACITENTAN—Oedema—Hydroxyurea—psoriasis	0.000921	0.00678	CcSEcCtD
MACITENTAN—Influenza—Triamcinolone—psoriasis	0.000918	0.00676	CcSEcCtD
MACITENTAN—Infection—Hydroxyurea—psoriasis	0.000915	0.00674	CcSEcCtD
MACITENTAN—Nervous system disorder—Hydroxyurea—psoriasis	0.000903	0.00665	CcSEcCtD
MACITENTAN—Bronchitis—Triamcinolone—psoriasis	0.000883	0.0065	CcSEcCtD
MACITENTAN—Anaemia—Mycophenolic acid—psoriasis	0.000873	0.00643	CcSEcCtD
MACITENTAN—Pharyngitis—Cyclosporine—psoriasis	0.000872	0.00642	CcSEcCtD
MACITENTAN—Infestation—Hydrocortisone—psoriasis	0.000869	0.0064	CcSEcCtD
MACITENTAN—Infestation NOS—Hydrocortisone—psoriasis	0.000869	0.0064	CcSEcCtD
MACITENTAN—Pharyngitis—Mycophenolate mofetil—psoriasis	0.00085	0.00626	CcSEcCtD
MACITENTAN—Headache—Calcitriol—psoriasis	0.000826	0.00608	CcSEcCtD
MACITENTAN—Angiopathy—Cyclosporine—psoriasis	0.000797	0.00587	CcSEcCtD
MACITENTAN—Angiopathy—Mycophenolate mofetil—psoriasis	0.000777	0.00573	CcSEcCtD
MACITENTAN—Oedema—Mycophenolic acid—psoriasis	0.000771	0.00568	CcSEcCtD
MACITENTAN—Infection—Mycophenolic acid—psoriasis	0.000766	0.00564	CcSEcCtD
MACITENTAN—Nervous system disorder—Mycophenolic acid—psoriasis	0.000756	0.00557	CcSEcCtD
MACITENTAN—Headache—Acitretin—psoriasis	0.000735	0.00541	CcSEcCtD
MACITENTAN—Headache—Fluocinolone Acetonide—psoriasis	0.000733	0.0054	CcSEcCtD
MACITENTAN—Pharyngitis—Triamcinolone—psoriasis	0.000729	0.00537	CcSEcCtD
MACITENTAN—Hypotension—Mycophenolic acid—psoriasis	0.000721	0.00531	CcSEcCtD
MACITENTAN—Anaemia—Cyclosporine—psoriasis	0.000707	0.0052	CcSEcCtD
MACITENTAN—Anaemia—Mycophenolate mofetil—psoriasis	0.000689	0.00508	CcSEcCtD
MACITENTAN—Oedema—Cyclosporine—psoriasis	0.000624	0.0046	CcSEcCtD
MACITENTAN—Infection—Cyclosporine—psoriasis	0.00062	0.00457	CcSEcCtD
MACITENTAN—Nervous system disorder—Cyclosporine—psoriasis	0.000612	0.00451	CcSEcCtD
MACITENTAN—Oedema—Mycophenolate mofetil—psoriasis	0.000609	0.00448	CcSEcCtD
MACITENTAN—Angiopathy—Dexamethasone—psoriasis	0.000605	0.00446	CcSEcCtD
MACITENTAN—Angiopathy—Betamethasone—psoriasis	0.000605	0.00446	CcSEcCtD
MACITENTAN—Infection—Mycophenolate mofetil—psoriasis	0.000605	0.00445	CcSEcCtD
MACITENTAN—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.000597	0.0044	CcSEcCtD
MACITENTAN—Headache—Hydroxyurea—psoriasis	0.000577	0.00425	CcSEcCtD
MACITENTAN—Hypotension—Mycophenolate mofetil—psoriasis	0.000569	0.00419	CcSEcCtD
MACITENTAN—Oedema—Prednisolone—psoriasis	0.000568	0.00418	CcSEcCtD
MACITENTAN—Oedema—Hydrocortisone—psoriasis	0.000554	0.00408	CcSEcCtD
MACITENTAN—Infection—Hydrocortisone—psoriasis	0.000551	0.00406	CcSEcCtD
MACITENTAN—Nervous system disorder—Hydrocortisone—psoriasis	0.000544	0.00401	CcSEcCtD
MACITENTAN—Infestation NOS—Methotrexate—psoriasis	0.000541	0.00398	CcSEcCtD
MACITENTAN—Infestation—Methotrexate—psoriasis	0.000541	0.00398	CcSEcCtD
MACITENTAN—Angiopathy—Prednisone—psoriasis	0.000527	0.00388	CcSEcCtD
MACITENTAN—Oedema—Triamcinolone—psoriasis	0.000522	0.00385	CcSEcCtD
MACITENTAN—Infection—Triamcinolone—psoriasis	0.000519	0.00382	CcSEcCtD
MACITENTAN—Hypotension—Hydrocortisone—psoriasis	0.000518	0.00382	CcSEcCtD
MACITENTAN—Headache—Mycophenolic acid—psoriasis	0.000483	0.00356	CcSEcCtD
MACITENTAN—Pharyngitis—Methotrexate—psoriasis	0.000482	0.00355	CcSEcCtD
MACITENTAN—Oedema—Betamethasone—psoriasis	0.000474	0.00349	CcSEcCtD
MACITENTAN—Oedema—Dexamethasone—psoriasis	0.000474	0.00349	CcSEcCtD
MACITENTAN—Infection—Betamethasone—psoriasis	0.000471	0.00347	CcSEcCtD
MACITENTAN—Infection—Dexamethasone—psoriasis	0.000471	0.00347	CcSEcCtD
MACITENTAN—Anaemia—Prednisone—psoriasis	0.000467	0.00344	CcSEcCtD
MACITENTAN—Nervous system disorder—Betamethasone—psoriasis	0.000465	0.00342	CcSEcCtD
MACITENTAN—Nervous system disorder—Dexamethasone—psoriasis	0.000465	0.00342	CcSEcCtD
MACITENTAN—Hypotension—Dexamethasone—psoriasis	0.000443	0.00326	CcSEcCtD
MACITENTAN—Hypotension—Betamethasone—psoriasis	0.000443	0.00326	CcSEcCtD
MACITENTAN—Angiopathy—Methotrexate—psoriasis	0.00044	0.00324	CcSEcCtD
MACITENTAN—Oedema—Prednisone—psoriasis	0.000413	0.00304	CcSEcCtD
MACITENTAN—Infection—Prednisone—psoriasis	0.00041	0.00302	CcSEcCtD
MACITENTAN—Nervous system disorder—Prednisone—psoriasis	0.000405	0.00298	CcSEcCtD
MACITENTAN—Headache—Cyclosporine—psoriasis	0.000391	0.00288	CcSEcCtD
MACITENTAN—Anaemia—Methotrexate—psoriasis	0.00039	0.00288	CcSEcCtD
MACITENTAN—Headache—Mycophenolate mofetil—psoriasis	0.000381	0.00281	CcSEcCtD
MACITENTAN—Headache—Prednisolone—psoriasis	0.000356	0.00262	CcSEcCtD
MACITENTAN—Headache—Hydrocortisone—psoriasis	0.000347	0.00256	CcSEcCtD
MACITENTAN—Infection—Methotrexate—psoriasis	0.000343	0.00252	CcSEcCtD
MACITENTAN—Nervous system disorder—Methotrexate—psoriasis	0.000338	0.00249	CcSEcCtD
MACITENTAN—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.000332	0.0861	CbGpPWpGaD
MACITENTAN—Headache—Triamcinolone—psoriasis	0.000327	0.00241	CcSEcCtD
MACITENTAN—Hypotension—Methotrexate—psoriasis	0.000322	0.00237	CcSEcCtD
MACITENTAN—Headache—Betamethasone—psoriasis	0.000297	0.00219	CcSEcCtD
MACITENTAN—Headache—Dexamethasone—psoriasis	0.000297	0.00219	CcSEcCtD
MACITENTAN—Headache—Prednisone—psoriasis	0.000258	0.0019	CcSEcCtD
MACITENTAN—Headache—Methotrexate—psoriasis	0.000216	0.00159	CcSEcCtD
MACITENTAN—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.000206	0.0534	CbGpPWpGaD
MACITENTAN—EDNRB—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000149	0.0387	CbGpPWpGaD
MACITENTAN—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000124	0.0321	CbGpPWpGaD
MACITENTAN—EDNRB—Peptide ligand-binding receptors—CCL20—psoriasis	0.000116	0.03	CbGpPWpGaD
MACITENTAN—EDNRB—GPCR ligand binding—HCAR2—psoriasis	0.000114	0.0295	CbGpPWpGaD
MACITENTAN—EDNRA—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000107	0.0277	CbGpPWpGaD
MACITENTAN—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	8.56e-05	0.0222	CbGpPWpGaD
MACITENTAN—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	8.44e-05	0.0219	CbGpPWpGaD
MACITENTAN—EDNRA—Peptide ligand-binding receptors—CCL20—psoriasis	8.28e-05	0.0215	CbGpPWpGaD
MACITENTAN—EDNRA—GPCR ligand binding—HCAR2—psoriasis	8.14e-05	0.0211	CbGpPWpGaD
MACITENTAN—EDNRB—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	7.76e-05	0.0201	CbGpPWpGaD
MACITENTAN—EDNRB—Endothelins—JUN—psoriasis	7.03e-05	0.0182	CbGpPWpGaD
MACITENTAN—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	6.94e-05	0.018	CbGpPWpGaD
MACITENTAN—ALB—HDL-mediated lipid transport—APOE—psoriasis	6.74e-05	0.0175	CbGpPWpGaD
MACITENTAN—EDNRB—GPCR downstream signaling—HCAR2—psoriasis	6.43e-05	0.0167	CbGpPWpGaD
MACITENTAN—EDNRB—GPCR ligand binding—CCL20—psoriasis	5.91e-05	0.0153	CbGpPWpGaD
MACITENTAN—EDNRB—Signaling by GPCR—HCAR2—psoriasis	5.84e-05	0.0151	CbGpPWpGaD
MACITENTAN—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	5.55e-05	0.0144	CbGpPWpGaD
MACITENTAN—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	5.14e-05	0.0133	CbGpPWpGaD
MACITENTAN—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	5.08e-05	0.0132	CbGpPWpGaD
MACITENTAN—EDNRA—Endothelins—JUN—psoriasis	5.03e-05	0.013	CbGpPWpGaD
MACITENTAN—EDNRA—GPCR downstream signaling—HCAR2—psoriasis	4.6e-05	0.0119	CbGpPWpGaD
MACITENTAN—EDNRA—GPCR ligand binding—CCL20—psoriasis	4.23e-05	0.011	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling by GPCR—HCAR2—psoriasis	4.18e-05	0.0108	CbGpPWpGaD
MACITENTAN—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	4.17e-05	0.0108	CbGpPWpGaD
MACITENTAN—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	4.11e-05	0.0107	CbGpPWpGaD
MACITENTAN—ALB—Lipoprotein metabolism—APOE—psoriasis	3.87e-05	0.01	CbGpPWpGaD
MACITENTAN—CYP2C19—Biological oxidations—CYP2S1—psoriasis	3.68e-05	0.00954	CbGpPWpGaD
MACITENTAN—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	3.63e-05	0.00941	CbGpPWpGaD
MACITENTAN—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	3.57e-05	0.00925	CbGpPWpGaD
MACITENTAN—EDNRB—Signaling Pathways—HCAR2—psoriasis	3.45e-05	0.00894	CbGpPWpGaD
MACITENTAN—EDNRB—GPCR downstream signaling—CCL20—psoriasis	3.34e-05	0.00865	CbGpPWpGaD
MACITENTAN—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	3.25e-05	0.00842	CbGpPWpGaD
MACITENTAN—ALB—Hemostasis—SERPINB8—psoriasis	3.16e-05	0.00818	CbGpPWpGaD
MACITENTAN—EDNRB—Peptide ligand-binding receptors—CXCL8—psoriasis	3.12e-05	0.00809	CbGpPWpGaD
MACITENTAN—EDNRB—Signaling by GPCR—CCL20—psoriasis	3.03e-05	0.00786	CbGpPWpGaD
MACITENTAN—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOE—psoriasis	3.02e-05	0.00781	CbGpPWpGaD
MACITENTAN—EDNRB—Signaling Pathways—TAGAP—psoriasis	2.99e-05	0.00775	CbGpPWpGaD
MACITENTAN—ALB—Folate Metabolism—CAT—psoriasis	2.65e-05	0.00687	CbGpPWpGaD
MACITENTAN—ALB—Vitamin B12 Metabolism—CRP—psoriasis	2.59e-05	0.00671	CbGpPWpGaD
MACITENTAN—ALB—Lipid and lipoprotein metabolism—APOE—psoriasis	2.57e-05	0.00667	CbGpPWpGaD
MACITENTAN—ALB—Vitamin B12 Metabolism—APOE—psoriasis	2.53e-05	0.00656	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—HCAR2—psoriasis	2.47e-05	0.0064	CbGpPWpGaD
MACITENTAN—ALB—Folate Metabolism—IL4—psoriasis	2.44e-05	0.00631	CbGpPWpGaD
MACITENTAN—EDNRA—GPCR downstream signaling—CCL20—psoriasis	2.39e-05	0.00619	CbGpPWpGaD
MACITENTAN—ALB—Vitamin B12 Metabolism—ICAM1—psoriasis	2.38e-05	0.00616	CbGpPWpGaD
MACITENTAN—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	2.36e-05	0.00612	CbGpPWpGaD
MACITENTAN—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	2.33e-05	0.00603	CbGpPWpGaD
MACITENTAN—EDNRA—Peptide ligand-binding receptors—CXCL8—psoriasis	2.24e-05	0.00579	CbGpPWpGaD
MACITENTAN—CYP3A4—Biological oxidations—CYP2S1—psoriasis	2.22e-05	0.00574	CbGpPWpGaD
MACITENTAN—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	2.18e-05	0.00566	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling by GPCR—CCL20—psoriasis	2.17e-05	0.00562	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—TAGAP—psoriasis	2.14e-05	0.00554	CbGpPWpGaD
MACITENTAN—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	2.12e-05	0.0055	CbGpPWpGaD
MACITENTAN—ALB—Selenium Micronutrient Network—CAT—psoriasis	2.11e-05	0.00546	CbGpPWpGaD
MACITENTAN—ALB—Folate Metabolism—CRP—psoriasis	2.11e-05	0.00546	CbGpPWpGaD
MACITENTAN—EDNRB—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.1e-05	0.00543	CbGpPWpGaD
MACITENTAN—ALB—Folate Metabolism—ICAM1—psoriasis	1.94e-05	0.00501	CbGpPWpGaD
MACITENTAN—CYP3A4—Tryptophan metabolism—CAT—psoriasis	1.91e-05	0.00495	CbGpPWpGaD
MACITENTAN—ALB—Vitamin B12 Metabolism—IFNG—psoriasis	1.81e-05	0.00469	CbGpPWpGaD
MACITENTAN—EDNRB—Signaling Pathways—CCL20—psoriasis	1.79e-05	0.00464	CbGpPWpGaD
MACITENTAN—ALB—Selenium Micronutrient Network—CRP—psoriasis	1.67e-05	0.00433	CbGpPWpGaD
MACITENTAN—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	1.65e-05	0.00427	CbGpPWpGaD
MACITENTAN—EDNRB—GPCR ligand binding—CXCL8—psoriasis	1.6e-05	0.00413	CbGpPWpGaD
MACITENTAN—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.59e-05	0.00412	CbGpPWpGaD
MACITENTAN—ALB—Selenium Micronutrient Network—ICAM1—psoriasis	1.54e-05	0.00398	CbGpPWpGaD
MACITENTAN—ALB—SLC-mediated transmembrane transport—CP—psoriasis	1.51e-05	0.00391	CbGpPWpGaD
MACITENTAN—ALB—Vitamin B12 Metabolism—NFKB1—psoriasis	1.51e-05	0.0039	CbGpPWpGaD
MACITENTAN—EDNRA—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.5e-05	0.00389	CbGpPWpGaD
MACITENTAN—ALB—Folate Metabolism—IFNG—psoriasis	1.47e-05	0.00382	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—CCL20—psoriasis	1.28e-05	0.00332	CbGpPWpGaD
MACITENTAN—ALB—Folate Metabolism—NFKB1—psoriasis	1.23e-05	0.00317	CbGpPWpGaD
MACITENTAN—ALB—Vitamin B12 Metabolism—TNF—psoriasis	1.17e-05	0.00304	CbGpPWpGaD
MACITENTAN—ALB—Selenium Micronutrient Network—IFNG—psoriasis	1.17e-05	0.00303	CbGpPWpGaD
MACITENTAN—EDNRA—GPCR ligand binding—CXCL8—psoriasis	1.14e-05	0.00296	CbGpPWpGaD
MACITENTAN—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.14e-05	0.00295	CbGpPWpGaD
MACITENTAN—EDNRB—Signaling Pathways—SOCS1—psoriasis	9.87e-06	0.00256	CbGpPWpGaD
MACITENTAN—ALB—Selenium Micronutrient Network—NFKB1—psoriasis	9.74e-06	0.00252	CbGpPWpGaD
MACITENTAN—ALB—Platelet degranulation—VEGFA—psoriasis	9.54e-06	0.00247	CbGpPWpGaD
MACITENTAN—ALB—Folate Metabolism—TNF—psoriasis	9.53e-06	0.00247	CbGpPWpGaD
MACITENTAN—ALB—Vitamin B12 Metabolism—IL6—psoriasis	9.46e-06	0.00245	CbGpPWpGaD
MACITENTAN—EDNRB—Signaling by GPCR—TYK2—psoriasis	9.41e-06	0.00244	CbGpPWpGaD
MACITENTAN—ALB—Hemostasis—ITGAL—psoriasis	9.18e-06	0.00238	CbGpPWpGaD
MACITENTAN—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	9.09e-06	0.00235	CbGpPWpGaD
MACITENTAN—EDNRB—GPCR downstream signaling—CXCL8—psoriasis	9.02e-06	0.00234	CbGpPWpGaD
MACITENTAN—ALB—Folate Metabolism—TP53—psoriasis	8.41e-06	0.00218	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—NDUFA5—psoriasis	8.25e-06	0.00214	CbGpPWpGaD
MACITENTAN—EDNRB—Signaling by GPCR—CXCL8—psoriasis	8.19e-06	0.00212	CbGpPWpGaD
MACITENTAN—ALB—Metabolism of lipids and lipoproteins—CARM1—psoriasis	7.7e-06	0.00199	CbGpPWpGaD
MACITENTAN—ALB—Folate Metabolism—IL6—psoriasis	7.69e-06	0.00199	CbGpPWpGaD
MACITENTAN—ALB—Transmembrane transport of small molecules—CP—psoriasis	7.67e-06	0.00199	CbGpPWpGaD
MACITENTAN—ALB—Selenium Micronutrient Network—TNF—psoriasis	7.57e-06	0.00196	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—NDUFA5—psoriasis	7.41e-06	0.00192	CbGpPWpGaD
MACITENTAN—ALB—Transmembrane transport of small molecules—CARM1—psoriasis	7.32e-06	0.0019	CbGpPWpGaD
MACITENTAN—EDNRB—Signaling Pathways—LEP—psoriasis	7.28e-06	0.00189	CbGpPWpGaD
MACITENTAN—EDNRB—Signaling Pathways—APOE—psoriasis	7.28e-06	0.00189	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—SOCS1—psoriasis	7.06e-06	0.00183	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—CYP2S1—psoriasis	7.02e-06	0.00182	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	6.91e-06	0.00179	CbGpPWpGaD
MACITENTAN—EDNRB—Signaling Pathways—NFKBIA—psoriasis	6.78e-06	0.00176	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling by GPCR—TYK2—psoriasis	6.73e-06	0.00174	CbGpPWpGaD
MACITENTAN—EDNRA—GPCR downstream signaling—CXCL8—psoriasis	6.46e-06	0.00167	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—CYP2S1—psoriasis	6.3e-06	0.00163	CbGpPWpGaD
MACITENTAN—ALB—Selenium Micronutrient Network—IL6—psoriasis	6.11e-06	0.00158	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling by GPCR—CXCL8—psoriasis	5.86e-06	0.00152	CbGpPWpGaD
MACITENTAN—EDNRB—Signaling Pathways—TYK2—psoriasis	5.56e-06	0.00144	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—LEP—psoriasis	5.21e-06	0.00135	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—APOE—psoriasis	5.21e-06	0.00135	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—NFKBIA—psoriasis	4.86e-06	0.00126	CbGpPWpGaD
MACITENTAN—EDNRB—Signaling Pathways—CXCL8—psoriasis	4.84e-06	0.00125	CbGpPWpGaD
MACITENTAN—EDNRB—Signaling by GPCR—IL6—psoriasis	4.6e-06	0.00119	CbGpPWpGaD
MACITENTAN—EDNRB—Signaling Pathways—JUN—psoriasis	4.5e-06	0.00117	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—NDUFA5—psoriasis	4.46e-06	0.00115	CbGpPWpGaD
MACITENTAN—EDNRB—Signaling Pathways—NFKB1—psoriasis	4.33e-06	0.00112	CbGpPWpGaD
MACITENTAN—ALB—Platelet activation, signaling and aggregation—VEGFA—psoriasis	4.23e-06	0.0011	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—TYK2—psoriasis	3.98e-06	0.00103	CbGpPWpGaD
MACITENTAN—EDNRB—Signaling Pathways—VEGFA—psoriasis	3.93e-06	0.00102	CbGpPWpGaD
MACITENTAN—EDNRB—Signaling Pathways—STAT3—psoriasis	3.89e-06	0.00101	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—CYP2S1—psoriasis	3.79e-06	0.000981	CbGpPWpGaD
MACITENTAN—ALB—Hemostasis—NOS2—psoriasis	3.76e-06	0.000975	CbGpPWpGaD
MACITENTAN—ALB—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.68e-06	0.000953	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—CXCL8—psoriasis	3.46e-06	0.000897	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—CARM1—psoriasis	3.43e-06	0.000888	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.3e-06	0.000855	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling by GPCR—IL6—psoriasis	3.29e-06	0.000853	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—JUN—psoriasis	3.22e-06	0.000834	CbGpPWpGaD
MACITENTAN—ALB—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.2e-06	0.00083	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—NFKB1—psoriasis	3.1e-06	0.000803	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—CARM1—psoriasis	3.08e-06	0.000797	CbGpPWpGaD
MACITENTAN—EDNRB—Signaling Pathways—TP53—psoriasis	2.97e-06	0.000769	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.88e-06	0.000745	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—VEGFA—psoriasis	2.81e-06	0.000729	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—STAT3—psoriasis	2.78e-06	0.000721	CbGpPWpGaD
MACITENTAN—EDNRB—Signaling Pathways—IL6—psoriasis	2.72e-06	0.000704	CbGpPWpGaD
MACITENTAN—ALB—Hemostasis—VEGFA—psoriasis	2.18e-06	0.000565	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—TP53—psoriasis	2.13e-06	0.00055	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—CAT—psoriasis	2.11e-06	0.000546	CbGpPWpGaD
MACITENTAN—EDNRA—Signaling Pathways—IL6—psoriasis	1.95e-06	0.000504	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—CAT—psoriasis	1.89e-06	0.00049	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—CARM1—psoriasis	1.85e-06	0.000479	CbGpPWpGaD
MACITENTAN—ALB—Hemostasis—TP53—psoriasis	1.65e-06	0.000427	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—APOE—psoriasis	1.64e-06	0.000424	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—APOE—psoriasis	1.47e-06	0.000381	CbGpPWpGaD
MACITENTAN—ALB—Metabolism—PPARG—psoriasis	1.43e-06	0.00037	CbGpPWpGaD
MACITENTAN—CYP2C19—Metabolism—PPARG—psoriasis	1.28e-06	0.000332	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—CAT—psoriasis	1.14e-06	0.000295	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—APOE—psoriasis	8.84e-07	0.000229	CbGpPWpGaD
MACITENTAN—CYP3A4—Metabolism—PPARG—psoriasis	7.7e-07	0.0002	CbGpPWpGaD
